Program
nilvanstomig
Also written as “ZG005 for Injection”, “ZG005” and “ZG005 Powder for Injection”.
Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Neuroendocrine · Uterine Cervical Neoplasms · Carcinoma, Non-Small-Cell Lung · Lymphoma, led by Suzhou Zelgen Biopharmaceuticals.
Furthest: phase 3, since Sep 4, 202615 company-led studies, 13 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals | 1513 open or running | phase 3since Sep 4, 2026 | Jan 22, 2024 | Apr 2027phase 2 · NCT06903377 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 22, 2024First studies: 3 phase 2 studiesFirst studyNCT06233292, NCT06239298, NCT06241235
- Apr 15, 2024Phase 2 study in Carcinoma, NeuroendocrineNCT06372626 · 93 planned · China
- Aug 14, 2024Phase 2 study in Carcinoma, HepatocellularNCT06558227 · 90 planned · China
- Mar 13, 20252 phase 2 studiesNCT06883526, NCT06903377
- Apr 7, 20252 phase 2 studies in Advanced Solid TumorNCT06938880, NCT06927687
- Jun 18, 2025Phase 2 study in Small Cell Lung CarcinomaNCT07038096 · 350 planned · China
- Jul 14, 20252 phase 2 studiesNCT07080216, NCT07099547
- Aug 19, 2025Phase 2 study in Advanced Solid TumorNCT07142837 · 153 planned · China
- Sep 4, 20262 phase 3 studiesPhase 3 reachedNCT07813572, NCT07833839
Ahead
- Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06903377
- Apr 2027Primary completion: phase 2 study in LymphomaNCT06883526
- May 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06938880
- May 2027Primary completion: phase 2 study in Advanced Solid TumorNCT06927687
TargetBeta
“A humanized bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhi”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rilvegostomig | AstraZeneca | phase 3 | 24 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07833839Carcinoma, Neuroendocrine · China | 3 | Not yet recruiting | Oct 2031 | 440 |
| NCT07813572Carcinoma, Hepatocellular · China | 3 | Recruiting | Sep 2031 | 600 |
| NCT07142837Advanced Solid Tumor · China | 2 | Not yet recruiting | Oct 2027 | 153 |
| NCT07099547Biliary Tract Carcinoma · China | 2 | Recruiting | Dec 2027 | 60 |
| NCT07080216Uterine Cervical Neoplasms · China | 2 | Recruiting | Aug 2027 | 120 |
| NCT07038096Small Cell Lung Carcinoma · China | 2 | Recruiting | Sep 2027 | 350 |
| NCT06938880Advanced Solid Tumor · China | 2 | Recruiting | May 2027 | 60 |
| NCT06927687Advanced Solid Tumor · China | 2 | Active, not recruiting | May 2027 | 50 |
| NCT06903377Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Apr 2027 | 50 |
| NCT06883526Lymphoma · China | 2 | Recruiting | Apr 2027 | 60 |
| NCT06558227Carcinoma, Hepatocellular · China | 2 | Recruiting | Sep 2026 | 90 |
| NCT06372626Carcinoma, Neuroendocrine · China | 2 | Recruiting | Jul 2026 | 93 |
| NCT06241235Uterine Cervical Neoplasms · China | 2 | Recruiting | May 2026 | 48 |
| NCT06239298Solid Tumor · China | 2 | UNKNOWN | Mar 2026 | 130 |
| NCT06233292Solid Tumors · China | 2 | Completed | Jul 22, 2026 | 125 |
How it is read
Names in the registry
- “ZG005 for Injection”, 7 entries
- “ZG005”, 5 entries
- “ZG005 Powder for Injection”, 4 entries
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 2 studies
- Carcinoma, Neuroendocrine, 2 studies
- Uterine Cervical Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.